Evidence map›Paper›PMID 36581770›Full record

ArticleNature materials2023

Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer.

Emanuela Frittoli, Andrea Palamidessi, Fabio Iannelli, Federica Zanardi, Stefano Villa, Leonardo Barzaghi, Hind Abdo, Valeria Cancila, Galina V Beznoussenko, Giulia Della Chiara and 37 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Nature materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Changes in Tissue Fluidity Predict Tumor Aggressiveness In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Pooled it
  3. Review
  4. Cell jamming transition is regulated by mitochondrial pyruvate transport and endocytosis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Beyond the membrane: rethinking EGFR signaling in physiology and cancer.Cellular and molecular life sciences : CMLS · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors at 13 institutions in 6 countries.

Emanuela Frittoli *IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Andrea Palamidessi *IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy. andrea.palamidessi@ifom.eu.ORCID 0000-0002-7134-7023
Fabio IannelliIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-2777-1417
Federica ZanardiIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Stefano VillaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy.
Leonardo BarzaghiIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-3174-6441
Hind AbdoIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Valeria CancilaDepartment of Health Sciences, Human Pathology Section, University of Palermo School of Medicine, Palermo, Italy.
Galina V BeznoussenkoIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-1876-4098
Giulia Della ChiaraIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0001-5211-3814
Massimiliano PaganiIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Chiara MalinvernoIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Dipanjan BhattacharyaIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-6409-4291
Federica PisatiIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Weimiao YuInstitute of Molecular and Cell Biology, A*STAR, Singapore, & Bioinformatics Institute, A*STAR, Singapore, Singapore.ORCID 0000-0001-5092-1009
Viviana GalimbertiEuropean Institute of Oncology (IEO) IRCCS, Milan, Italy.
Giuseppina BonizziEuropean Institute of Oncology (IEO) IRCCS, Milan, Italy.
Emanuele MartiniIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0002-3375-7726
Alexander A MironovIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Ubaldo GioiaIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Flora AscioneIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Qingsen LiIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Kristina HavasIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Serena MagniIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0003-4730-9710
Zeno LavagninoIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Fabrizio Andrea PennacchioIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Paolo MaiuriIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.ORCID 0000-0001-5079-445X
Silvia CaponiIstituto Officina dei Materiali, National Research Council (IOM-CNR), Unit of Perugia, c/o Department of Physics and Geology, University of Perugia, Perugia, Italy.ORCID 0000-0002-4219-3256
Maurizio MattarelliDepartment of Physics and Geology, University of Perugia, Perugia, Italy.ORCID 0000-0001-9184-7968
Sabata MartinoDepartment of Chemistry, Biology and Biotechnology, Biochemical and Biotechnological Sciences, University of Perugia, Perugia, Italy.
Fabrizio d'Adda di FagagnaIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Chiara RossiUnit of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.ORCID 0000-0002-9253-1671
Marco LucioniUnit of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Richard TancrediMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Paolo PedrazzoliMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-9419-7160
Andrea VecchioneDepartment of Clinical and Molecular Medicine, University of Roma, La Sapienza, Rome, Italy.ORCID 0000-0002-5497-6856
Cristiano PetriniIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Francesco FerrariIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Chiara LanzuoloInstitute of Biomedical Technologies, National Research Council, Milan, Italy.
Giovanni BertalotDepartment of Pathology, S. Chiara Hospital, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
Guilherme NaderInstitut Curie and Institut Pierre Gilles de Gennes, PSL Research University, CNRS, UMR-144, Paris, France.
Marco FoianiIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.
Matthieu PielInstitut Curie and Institut Pierre Gilles de Gennes, PSL Research University, CNRS, UMR-144, Paris, France.ORCID 0000-0002-2848-177X
Roberto CerbinoDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy.ORCID 0000-0003-0434-7741
Fabio GiavazziDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy. fabio.giavazzi@unimi.it.ORCID 0000-0003-4930-0592
Claudio TripodoIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy. claudio.tripodo@unipa.it.ORCID 0000-0002-0821-6231
Giorgio ScitaIFOM, the FIRC Institute of Molecular Oncology, Milan, Italy. giorgio.scita@ifom.eu.ORCID 0000-0001-7984-1889
IFOM · ITUniversity of Milan · ITUniversity of Pavia · ITUniversity of Perugia · ITCentre National de la Recherche Scientifique · FRIstituti di Ricovero e Cura a Carattere Scientifico · ITAgency for Science, Technology and Research · SGASST Melegnano e della Martesana · ITInstitute of Biomedical Technologies · ITSapienza University of Rome · ITUniversity of Palermo · ITUniversity of Trento · ITUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The process in which locally confined epithelial malignancies progressively evolve into invasive cancers is often promoted by unjamming, a phase transition from a solid-like to a liquid-like state, which occurs in various tissues. Whether this tissue-level mechanical transition impacts phenotypes during carcinoma progression remains unclear. Here we report that the large fluctuations in cell density that accompany unjamming result in repeated mechanical deformations of cells and nuclei. This triggers a cellular mechano-protective mechanism involving an increase in nuclear size and rigidity, heterochromatin redistribution and remodelling of the perinuclear actin architecture into actin rings. The chronic strains and stresses associated with unjamming together with the reduction of Lamin B1 levels eventually result in DNA damage and nuclear envelope ruptures, with the release of cytosolic DNA that activates a cGAS-STING (cyclic GMP-AMP synthase-signalling adaptor stimulator of interferon genes)-dependent cytosolic DNA response gene program. This mechanically driven transcriptional rewiring ultimately alters the cell state, with the emergence of malignant traits, including epithelial-to-mesenchymal plasticity phenotypes and chemoresistance in invasive breast carcinoma.

Indexed as

ActinsNeoplasmsCytosolDNANucleotidyltransferasesSignal TransductionActinsDNANucleotidyltransferases

Identifiers

PMID36581770
PMCPMC10156599
OpenAlexW4313312838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.